{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:31:32Z","timestamp":1787311892400,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75754-7","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:13:52Z","timestamp":1784301232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-26-driven epigenetic remodeling promotes immune evasion in colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-1042","authenticated-orcid":false,"given":"Takumi","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-7275","authenticated-orcid":false,"given":"Ryo","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-310X","authenticated-orcid":false,"given":"Kazuyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2261-725X","authenticated-orcid":false,"given":"Jinghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-9391","authenticated-orcid":false,"given":"Shogo","family":"Ehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-0973","authenticated-orcid":false,"given":"Shuji","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8828","authenticated-orcid":false,"given":"Hiroshi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Tomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"75754_CR1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley, C. C., Zehn, D., Gottschalk, S. & Chi, H. T cell dysfunction and therapeutic intervention in cancer. Nat. Immunol. 25, 1344\u20131354 (2024).","journal-title":"Nat. Immunol."},{"key":"75754_CR2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med"},{"key":"75754_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11\u201319 (2020).","journal-title":"J. Clin. Oncol."},{"key":"75754_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"75754_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med"},{"key":"75754_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51, 27\u201341 (2019).","journal-title":"Immunity"},{"key":"75754_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"75754_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct. Target Ther. 6, 263 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"75754_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20, 485\u2013503 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"75754_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16, 431\u2013446 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"75754_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick, C. C. & Malanchi, I. Neutrophils in cancer: heterogeneous and multifaceted. Nat. Rev. Immunol. 22, 173\u2013187 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"75754_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35096-6","volume":"13","author":"Q Sui","year":"2022","unstructured":"Sui, Q. et al. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat. Commun. 13, 7316 (2022).","journal-title":"Nat. Commun."},{"key":"75754_CR13","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734\u20134752 e4720 (2021).","journal-title":"Cell"},{"key":"75754_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33377-8","volume":"13","author":"RW Zhou","year":"2022","unstructured":"Zhou, R. W. et al. A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nat. Commun. 13, 6041 (2022).","journal-title":"Nat. Commun."},{"key":"75754_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.immuni.2014.03.010","volume":"40","author":"I Kryczek","year":"2014","unstructured":"Kryczek, I. et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40, 772\u2013784 (2014).","journal-title":"Immunity"},{"key":"75754_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24843-w","volume":"12","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nat. Commun. 12, 4560 (2021).","journal-title":"Nat. Commun."},{"key":"75754_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2020-218189","volume":"80","author":"H Tsuchiya","year":"2021","unstructured":"Tsuchiya, H. et al. Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis. Ann. Rheum. Dis. 80, 440\u2013450 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"75754_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","volume":"12","author":"EA Akbay","year":"2017","unstructured":"Akbay, E. A. et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J. Thorac. Oncol. 12, 1268\u20131279 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"75754_CR19","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-19-0114","volume":"25","author":"NJ Llosa","year":"2019","unstructured":"Llosa, N. J. et al. Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 25, 5250\u20135259 (2019).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"75754_CR20","doi-asserted-by":"crossref","unstructured":"Liu C. et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J. Immunother. Cancer 9, e001895 (2021).","DOI":"10.1136\/jitc-2020-001895"},{"key":"75754_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/gut.2007.130112","volume":"58","author":"J Dambacher","year":"2009","unstructured":"Dambacher, J. et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58, 1207\u20131217 (2009).","journal-title":"Gut"},{"key":"75754_CR22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1164\/rccm.201404-0689OC","volume":"190","author":"KF Che","year":"2014","unstructured":"Che, K. F. et al. Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization. Am. J. Respir. Crit. Care Med 190, 1022\u20131031 (2014).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"75754_CR23","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.jid.2023.12.018","volume":"144","author":"K Bier","year":"2024","unstructured":"Bier, K. et al. IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1b. J. Investig. Dermatol. 144, 1544\u20131556 e1549 (2024).","journal-title":"J. Investig. Dermatol."},{"key":"75754_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jid.2018.09.037","volume":"139","author":"T Itoh","year":"2019","unstructured":"Itoh, T. et al. Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis.  J. Investigative Dermatol. 139, 878\u2013889 (2019).","journal-title":"J. Investigative Dermatol."},{"key":"75754_CR25","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/s41591-020-1003-4","volume":"26","author":"D Corridoni","year":"2020","unstructured":"Corridoni, D. et al. Single-cell atlas of colonic CD8(+) T cells in ulcerative colitis. Nat. Med 26, 1480\u20131490 (2020).","journal-title":"Nat. Med"},{"key":"75754_CR26","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1158\/0008-5472.CAN-18-3825","volume":"80","author":"TN Trotter","year":"2020","unstructured":"Trotter, T. N. et al. IL26, a noncanonical mediator of DNA inflammatory stimulation, promotes TNBC engraftment and progression in association with neutrophils. Cancer Res 80, 3088\u20133100 (2020).","journal-title":"Cancer Res"},{"key":"75754_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03787-5","volume":"12","author":"T Itoh","year":"2021","unstructured":"Itoh, T. et al. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis. 12, 520 (2021).","journal-title":"Cell Death Dis."},{"key":"75754_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/JLB.1MA0221-479RR","volume":"110","author":"Y Niu","year":"2021","unstructured":"Niu, Y. et al. IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4(+) IL-22(+) T-cell differentiation and inhibiting CD8(+) T-cell cytotoxicity. J. Leukoc. Biol. 110, 39\u201352 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"75754_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32627-z","volume":"13","author":"K Sun","year":"2022","unstructured":"Sun, K. et al. scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory. Nat. Commun. 13, 4943 (2022).","journal-title":"Nat. Commun."},{"key":"75754_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16363-w","volume":"11","author":"LG Perez","year":"2020","unstructured":"Perez, L. G. et al. TGF-beta signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. Nat. Commun. 11, 2608 (2020).","journal-title":"Nat. Commun."},{"key":"75754_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature11465","volume":"491","author":"SI Grivennikov","year":"2012","unstructured":"Grivennikov, S. I. et al. Adenoma-linked barrier defects and microbial products drive IL-23\/IL-17-mediated tumour growth. Nature 491, 254\u2013258 (2012).","journal-title":"Nature"},{"key":"75754_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"J Li","year":"2023","unstructured":"Li, J. et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell 41, 1152\u20131169 e1157 (2023).","journal-title":"Cancer Cell"},{"key":"75754_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02424-0","volume":"9","author":"M Efremova","year":"2018","unstructured":"Efremova, M. et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat. Commun. 9, 32 (2018).","journal-title":"Nat. Commun."},{"key":"75754_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","volume":"24","author":"H Katoh","year":"2013","unstructured":"Katoh, H. et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24, 631\u2013644 (2013).","journal-title":"Cancer Cell"},{"key":"75754_CR35","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1158\/0008-5472.CAN-16-3199","volume":"77","author":"D Wang","year":"2017","unstructured":"Wang, D., Sun, H., Wei, J., Cen, B. & DuBois, R. N. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. Cancer Res 77, 3655\u20133665 (2017).","journal-title":"Cancer Res"},{"key":"75754_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/1477-3163.78279","volume":"10","author":"M De Robertis","year":"2011","unstructured":"De Robertis, M. et al. The AOM\/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog. 10, 9 (2011).","journal-title":"J. Carcinog."},{"key":"75754_CR37","doi-asserted-by":"publisher","first-page":"33343","DOI":"10.1074\/jbc.M405000200","volume":"279","author":"S Hor","year":"2004","unstructured":"Hor, S. et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains.  J. Biol. Chem. 279, 33343\u201333351 (2004).","journal-title":"J. Biol. Chem."},{"key":"75754_CR38","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1128\/JVI.74.8.3881-3887.2000","volume":"74","author":"A Knappe","year":"2000","unstructured":"Knappe, A., Hor, S., Wittmann, S. & Fickenscher, H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J. Virol. 74, 3881\u20133887 (2000).","journal-title":"J. Virol."},{"key":"75754_CR39","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1021\/nn4057269","volume":"8","author":"DM Copolovici","year":"2014","unstructured":"Copolovici, D. M., Langel, K., Eriste, E. & Langel, U. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8, 1972\u20131994 (2014).","journal-title":"ACS Nano"},{"key":"75754_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0962-8924(01)02064-5","volume":"11","author":"V Baud","year":"2001","unstructured":"Baud, V. & Karin, M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11, 372\u2013377 (2001).","journal-title":"Trends Cell Biol."},{"key":"75754_CR41","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87, 2095\u20132147 (1996).","journal-title":"Blood"},{"key":"75754_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2014.08.027","volume":"159","author":"Z Liu","year":"2014","unstructured":"Liu, Z. et al. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159, 358\u2013373 (2014).","journal-title":"Cell"},{"key":"75754_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","volume":"56","author":"JD Brown","year":"2014","unstructured":"Brown, J. D. et al. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56, 219\u2013231 (2014).","journal-title":"Mol. Cell"},{"key":"75754_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/nar\/gkw826","volume":"45","author":"Z Najafova","year":"2017","unstructured":"Najafova, Z. et al. BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. Nucleic Acids Res 45, 127\u2013141 (2017).","journal-title":"Nucleic Acids Res"},{"key":"75754_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14400","volume":"8","author":"AJ Cohen","year":"2017","unstructured":"Cohen, A. J. et al. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat. Commun. 8, 14400 (2017).","journal-title":"Nat. Commun."},{"key":"75754_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41556-020-0491-2","volume":"22","author":"J Nishida","year":"2020","unstructured":"Nishida, J. et al. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat. Cell Biol. 22, 465\u2013475 (2020).","journal-title":"Nat. Cell Biol."},{"key":"75754_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"75754_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41423-023-01118-6","volume":"21","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Id2 epigenetically controls CD8(+) T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex. Cell Mol. Immunol. 21, 292\u2013308 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"75754_CR49","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/19420862.2019.1654305","volume":"11","author":"R Hatano","year":"2019","unstructured":"Hatano, R. et al. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. mAbs 11, 1428\u20131442 (2019).","journal-title":"mAbs"},{"key":"75754_CR50","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1111\/ajt.17178","volume":"22","author":"R Hatano","year":"2022","unstructured":"Hatano, R. et al. Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. Am. J. Transpl. 22, 2804\u20132820 (2022).","journal-title":"Am. J. Transpl."},{"key":"75754_CR51","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4049\/jimmunol.1000124","volume":"185","author":"PL Collins","year":"2010","unstructured":"Collins, P. L. et al. Distal regions of the human IFNG locus direct cell type-specific expression. J. Immunol. (Baltim., Md: 1950) 185, 1492\u20131501 (2010).","journal-title":"J. Immunol. (Baltim., Md: 1950)"},{"key":"75754_CR52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/gene.2012.22","volume":"13","author":"PL Collins","year":"2012","unstructured":"Collins, P. L., Henderson, M. A. & Aune, T. M. Lineage-specific adjacent IFNG and IL26 genes share a common distal enhancer element. Genes Immun. 13, 481\u2013488 (2012).","journal-title":"Genes Immun."},{"key":"75754_CR53","first-page":"5860","volume":"11","author":"VC Gibbs","year":"1991","unstructured":"Gibbs, V. C. et al. The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer. Mol. Cell Biol. 11, 5860\u20135866 (1991).","journal-title":"Mol. Cell Biol."},{"key":"75754_CR54","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","volume":"68","author":"Y Shinkai","year":"1992","unstructured":"Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855\u2013867 (1992).","journal-title":"Cell"},{"key":"75754_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17\u201327 (1994).","journal-title":"Cell"},{"key":"75754_CR56","doi-asserted-by":"publisher","first-page":"W39","DOI":"10.1093\/nar\/gkv416","volume":"43","author":"TL Bailey","year":"2015","unstructured":"Bailey, T. L., Johnson, J., Grant, C. E. & Noble, W. S. The MEME Suite. Nucleic Acids Res 43, W39\u2013W49 (2015).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75754-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:04:20Z","timestamp":1787310260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75754-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75754"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75754-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.I., R.H. Y.K., K.O., and C.M. are the inventors and patent holders of humanised anti-IL-26 mAb. Y.K. is the chief executive officer of Y\u2019s AC Co., Ltd, and N.H.D, K.O., and C.M. are stockholders of Y\u2019s AC Co., Ltd. Other authors declare no competing financial interests associated with this manuscript. Other authors declare no competing interests associated with this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8764"}}